FDA supportive of Efti registrational trial in lung cancer
Filed with ASX · · 2 pages · English
Story so far
Earlier from Immutep
- Approval to start Efti & Bavencio trial in urothelial cancer
- Immutep to announce new TACTI-002 data at ASCO 2023
- Response to ASX Aware Query
- Initiation of Phase 2 Trial for Efti in Soft Tissue Sarcoma
- Positive Final Data in 2nd Line Metastatic NSCLC Patients
Later from Immutep
- Excellent initial Overall Survival Benefit in 1st line NSCLC
- Promising New Data in 1st line NSCLC from INSIGHT-003 Trial
- 1st patient dosed in AIPAC-003 ph2/3 breast cancer trial
- Publication of Abstracts for ASCO 2023 Annual Meeting
- Charles River Laboratories to run IMP761 Toxicology Study
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep